These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1000139)

  • 41. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.
    Mattes JA
    J Clin Psychiatry; 1989 Oct; 50(10):389-91. PubMed ID: 2571612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
    Zedkova I; Dudova I; Urbanek T; Hrdlicka M
    Neuro Endocrinol Lett; 2011; 32(5):667-70. PubMed ID: 22167144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The atypical neuroleptic clozapine (Leponex)--current knowledge and recent clinical aspects].
    Klimke A; Klieser E
    Fortschr Neurol Psychiatr; 1995 May; 63(5):173-93. PubMed ID: 7782019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term experience with clozapine in Denmark: research and clinical practice.
    Gerlach J; Jørgensen EO; Peacock L
    Psychopharmacology (Berl); 1989; 99 Suppl():S92-6. PubMed ID: 2682734
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clozapine induced increase of human plasma norepinephrine.
    Sarafoff M; Davis L; Rüther E
    J Neural Transm; 1979; 46(2):175-80. PubMed ID: 512652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antipsychotic effect of clozapine. Clinical and animal-experiment-biochemical studies].
    Ackenheil M
    Fortschr Med; 1978 Feb; 96(5):220. PubMed ID: 620985
    [No Abstract]   [Full Text] [Related]  

  • 47. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.
    Seeman P
    Neuropsychopharmacology; 1992 Dec; 7(4):261-84. PubMed ID: 1362057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.
    Remvig J; Larsen H; Rask P; Skausig OB; Skov S; Strömgren LS
    Pharmacopsychiatry; 1987 Jul; 20(4):147-54. PubMed ID: 3615572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clozapine rechallenge after an episode of 'neuroleptic malignant syndrome'.
    Weller M; Kornhuber J
    Br J Psychiatry; 1992 Dec; 161():855-6. PubMed ID: 1362370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Influence of clozapine on neuroleptigenic extrapyramidal motor disturbances (author's transl)].
    Zander KJ; Rüther E
    Arzneimittelforschung; 1978; 28(9):1495-6. PubMed ID: 38808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Schizophrenically disordered time perception and its modification by neuroleptics].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1985 Jul; 37(7):410-5. PubMed ID: 4048304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study.
    Gelenberg AJ; Doller JC
    J Clin Psychiatry; 1979 May; 40(5):238-40. PubMed ID: 374401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
    Jiang LH; Kasser RJ; Altar CA; Wang RY
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes.
    Reuss B; Unsicker K
    Mol Cell Neurosci; 2001 Aug; 18(2):197-209. PubMed ID: 11520180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
    Kucharska-Pietura K; Mortimer A; Tylec A; Czernikiewicz A
    Clin Schizophr Relat Psychoses; 2012 Apr; 6(1):14-20. PubMed ID: 22453865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not gamma-butyrolactone-resistant dopamine release.
    Chrapusta SJ; Karoum F; Egan MF; Wyatt RJ
    Eur J Pharmacol; 1993 Mar; 233(1):135-42. PubMed ID: 8472742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clozapine: a neuroleptic at risk of provoking neuroleptic malignant syndrome (NMS) or an alternative neuroleptic with positive NMS case histories?].
    Weller M; Kornhuber J
    Fortschr Neurol Psychiatr; 1993 Jun; 61(6):217-22. PubMed ID: 8330832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine.
    Ellenbroek BA; Artz MT; Cools AR
    Eur J Pharmacol; 1991 Apr; 196(1):103-8. PubMed ID: 1678712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships.
    Bürki HR; Sayers AC; Ruch W; Asper H
    Arzneimittelforschung; 1977; 27(8):1561-5. PubMed ID: 20900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The risks and benefits of clozapine versus chlorpromazine.
    Claghorn J; Honigfeld G; Abuzzahab FS; Wang R; Steinbook R; Tuason V; Klerman G
    J Clin Psychopharmacol; 1987 Dec; 7(6):377-84. PubMed ID: 3323261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.